Association of CCR5 Δ32 deletion with early death in multiple sclerosis

Genetics in Medicine

Volumn 6, Issue 3, 2004, Pages 126-131

  Gade Andavolu, Radhika ^a   Comings, David E ^b   MacMurray, James ^b   Rostamkhani, Masoud ^b   Cheng, Li S C ^b   Tourtellotte, Wallace W ^c   Cone, Lawrence A ^a  

^a EISENHOWER MEDICAL CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Chemokine receptor; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Polymerase chain reaction

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 DELTA32; DNA; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; AUTOPSY; BRAIN TISSUE; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE MARKER; ENCEPHALITIS; ETHNIC GROUP; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE SCLEROSIS; PATHOGENESIS; PROGNOSIS; PROTEIN INTERACTION; RECEPTOR BINDING; STATISTICAL SIGNIFICANCE; SURVIVAL; T LYMPHOCYTE; TISSUE STRUCTURE; CASE CONTROL STUDY; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL RATE;

ALLELES; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CCR5; SEQUENCE DELETION; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 2642570186     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000127274.45301.54     Document Type: Article

References (43)

1. Karpus, W, J Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995;155:5003-5010.
2. Ransohoff RM. Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. J Neuroimmunol 1999;98:57-68.
3. Huang Y, Paxton WA, Wolinsky SM, Neumann A, Zhang L, He T et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
4. Biti R, French R, Young J, Bennetts B, Stewart G. HIV infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997;3:252-253.
5. O'Brien TR, Winkler C, Dean M, Nelson JAE, Carrington M, Michael NL. HIV-1 infection in an homozygous for CCR5 delta 32. Lancet 1997;349:1219-1220.
6. Mummidi S, Ahuja S, Gonzalez E, Anderson SA, Santiago EN, Stephan KT et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nature Med 1998;4:786-793.
7. de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999;163:4597-4603.
8. Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots K et al. Effects of plasma HIV RNA, CD4+ lymphocytes and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. JAIDS 1999;21:317-325.
9. Cone L. A, Espinoza G, Moreno A, Downs M. CC-CKR5 (CCR5) delta 32 alters the clinical course and immune status of HIV infection [abstract]. 13th Int. AIDS conference, Durban, South Africa, July 8-13, 2000;TuPeA 3107:320.
10. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5 (+) and CXCR3 (+) T cells are increased in multiple sclerosis and their ligands MIP-1 alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999;96:6873-6878.
11. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-15.
12. Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 2000;108:192-200.
13. Zhang GX, Baker CM, Kolson DL, Rostomi AM. Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. Mult Scler 2000;6:3-13.
14. Strunk T, Bubel S, Mascher B, Schlenke P, Kirchner H, Wandinger KP. Increased numbers of CCR5+ interferon-γ- and tumor necrosis factor α-secreting T lymphocytes in multiple sclerosis patients. Ann Neurol 2000;47:269-273.
15. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 1995;92:7440-7444.
16. Sanders VJ, Felisan S, Waddell A, Tourtellotte WW. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol 1996, Aug; 2: 249-258.
17. Knox KK, Brewer JH, Henry JM, Harington DJ, Carrigan DR. Human herpes virus 6 and multiple sclerosis. Systemic active infections in patients with early disease. Clin Infect Dis 2000;31:894-903.
18. Eikelenboom MJ, Killestein J, Izeboud T, Lalkers NF, van Lier RA, BarKhof F et al. Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. J Neuroimmunol 2002;133:225-232.
19. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A et al. Differential expression of chemokine receptors and chemotactic responsiveness of typel T helper cells (TH-1s) and TH-2s. J Exp Med 1998;187:129-134.
20. Paxton WA, Neumann AU, Kang S, Deutch L, Brown RC, Koup RA et al. RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immuno-deficiency virus type 1 disease progression. J Infect Dis 2001;183: 1678-1681.
21. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R et al. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 2000;165:6576-6582.
22. Ebers GC, Sadovnick AD. The role of genetic factors in multiple sclerosis susceptibility. J Neuroimmunol 1994;54:1-17.
23. Oksenberg JR, Seboun E, Hauser SL. Genetics of demyelinating diseases. Brain Pathol 1996;6:289-302.
24. Sawcer S, Jones HB, Feakes R, Gray J, Smaldon N, Chataway J et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996;13:464-468.
25. Hooper-van Veen T, Schrjver HM, Zwiers A, Crusius JB, Knol DL, Kalkers NF et al. The interleukin-1 gene family in multiple sclerosis susceptibility and disease course. Multi Scler 2003;9:535-539.
26. Teutsch SM, Booth DR, Bennetts BH, Heard RN, Stewart GJ. Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-alpha gene and their association with multiple sclerosis. Eur J Hum Genet 2003;11: 509-515.
27. Masterman T, Ligers A, Zhang Z, Heilgren D, Salter H, Anvret M et al. CTLA4 dimorphisms and the multiple sclerosis phenotype. J Neuroimmunology 2002;131: 208-212.
28. Schreiber K, Otura AB, Ryder LP, Madsen HO, Jorgensen OS, Sverjgaard A et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 2002;8:295-298.
29. Poser CM. The dissemination of multiple sclerosis: a Viking saga? A historical assay. Ann Neurol 1994;36:S231-S243.
30. Rosati G. The prevalence of Multiple sclerosis in the world: an update. Neurol Sci, Apr 2001;22:117-139.
31. Martinson JJ, Chapman NH, Rees DC, Liu Y. T, Clegg JB. Global distribution of the CCR5 gene 32 base pair deletion. Nat Genet 1997;16:100-102.
32. Lucotte G, Mercier G. Distribution of the CCR5 gene 32-bp deletion in Europe. J Acquire Immune Def Syn Hum Retro Virol 1998;19:174-177.
33. Siao CJ, Tsirka SE. Extracellular proteases and neuronal cell death. Cell Mol Biol (Noisy-le-grand) 2002;48:151-161.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
35. Cox DR, Oaks D. Analysis of survival data. London UK: Chapman & Hall, 1984.
36. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-59.
37. Midgard R, Albrektsen G, Riise T, Kvale G, Nyland H. Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in More and Romsdal, Norway. J Neurol Neurosurg Psychiatry 1995;58:417-421.
38. Barcellos LF, Schito AM, Rimmler JB, Vittinghoff E, Shih A, Lincoln R et al. CC-chemokine receptor 5 polymorphism and age at onset in familial sclerosis. Immunogenet 2000;51:281-288.
39. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 delta 32, matrix metallo- proteinase9 and disease activity in multiple sclerosis. J Neuroimmunol 2000;102:98-106.
40. Bennetts BH, Teutsch SM, Buhler MM, Heard RNS, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Human Immunol 1997;58:52-59.
41. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R et al. Genetic restriction of HIV-1 infection and progression of AIDS by a deletion allele of the CCR5 structural gene. Hemophilia growth and Development study. Multicenter AIDS Cohort study, Multicenter Hemophilia study, San Francisco Cohort study, Alive study. Science 1996;273:1856-1862.
42. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N. CCR levels and expression pattern correlate with the infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997;185:1681-1691.
43. Gade-Andavolu R, MacMurray J, Blake H, Muhleman D, Tourtellotte W, Comings DE. Association between γ-aminobutyric acid A3 receptor gene and Multiple Sclerosis. Arch Neurol 1998;55:513-516.